144/109 - Integration to Implementation (I to I) on Vitamin A interventions

Organized by: Microutrient Forum Canada (Canada)
Monday 16 October 11.30 - 13.30 h. Room 3

Introduction

Chair

Dr. Ian Darnton-Hill

Adjunct Professor. University of Sydney. Australia. Tufts University. USA.


Scope of the problem and overview of the controversy; how the I to I approach will be applied

Speaker

Dr. Daniel Raiten

Program Director Nutrition. Pediatric Growth and Nutrition Branch. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). National Institutes of Health (NIH). USA.


Biological evidence for or against high dose supplementation

Speaker

Dr. Sherry Tanumihardjo

University of Wisconsin. USA.


Relative strengths and weaknesses of available interventions/program strategies to prevent or improve vitamin A status in individuals or populations

Speaker

Dr. Emorn Udomkesmalee

Co-chair Independent Expert Group (IEG). The Global Nutrition Report. USA & Thailand.


See biography

Country perspective. What are the implications of the current concern/debate on national efforts to prevent vitamin A deficiency in Guatemala

Speaker

MSc. Dora Inés Mazariegos

Nutritional Biochemistry Lab. Institute of Nutrition of Central America and Panama (INCAP). Guatemala.


Country perspective. What are the implications of the current concern/debate on national efforts to prevent vitamin A deficiency in Zambia

Speaker

Dr. Musonda Mofu

Deputy Executive Director. National Food and Nutrition Commission of Zambia. Zambia.


What does it all mean and how might we move an agenda forward to address these challenges? A. Technical agencies

Speaker

Dr. Roland Kupka

Senior Advisor for Micronutrients. UNICEF. USA.


What does it all mean and how might we move an agenda forward to address these challenges? B. Clinical perspective

Speaker

Dr. Parminder S. Suchdev

Associate Professor of Pediatrics & Global Health. Emory University. Medical Epidemiologist. Nutrition Branch. Centers for Disease Control & Prevention. USA.


What does it all mean and how might we move an agenda forward to address these challenges? C. Enabling agencies

Speaker

Dr. Klaus Kraemer

Managing Director. Sight and Life. Switzerland. Adjunct Associate Professor. International Health Johns Hopkins Bloomberg School of Public Health. USA.